ESMO 2016

ESMO 2016

Potentially Practice-Changing: Ribociclib/Letrozole Combo in Advanced Breast Cancer

The addition of the selective CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival (PFS) in hormone receptor–positive (HR+) advanced breast cancer. Compared with letrozole alone, the combination of ribociclib/letrozole [ Read More ]

ESMO 2016

Published Studies Underreport Toxicities Associated with Targeted Therapy and Immunotherapy

Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented at [ Read More ]

ESMO 2016

Quality of Life Improved with Nivolumab versus Chemotherapy

In recent years, the cancer patient’s experience has been recognized as an important factor in determining the value of a treatment. According to patient reports, their quality of life (QOL) [ Read More ]